Literature DB >> 25249046

Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions.

Muhammad Amin1, Naeti Suksomboon.   

Abstract

The incidence of type 2 diabetes mellitus is increasing rapidly, as are the associated co-morbidities. Consequently, it has become necessary for a diabetic patient to take multiple medications at the same time to delay progression of the disease. This can put patients at an increased risk of moderate to severe drug interactions, which may threaten patients' life or may deteriorate the quality of their life. Hence, managing drug-drug interactions is the cornerstone of anti-diabetic therapy. Most of the clinically important drug-drug interactions of anti-diabetic agents are related to their metabolic pathways, but drugs that compete for renal excretion or impair renal status can also play an important role. In this review, we have examined the clinical implications and underlying mechanisms of drugs that are likely to alter the pharmacologic response of or cause adverse events with antidiabetic drugs, and we have outlined safe and efficacious treatment modalities.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25249046     DOI: 10.1007/s40264-014-0223-2

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  112 in total

1.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

2.  Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.

Authors:  M Niemi; P J Neuvonen; K T Kivistö
Journal:  Clin Pharmacol Ther       Date:  2001-11       Impact factor: 6.875

3.  Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.

Authors:  M Niemi; J T Backman; M Neuvonen; J Laitila; P J Neuvonen; K T Kivistö
Journal:  Clin Pharmacol Ther       Date:  2001-04       Impact factor: 6.875

4.  Chlorpromazine induced diabetes.

Authors:  C Korenyi; B Lowenstein
Journal:  Dis Nerv Syst       Date:  1968-12

5.  Hypoglycaemia due to azapropazone-tolbutamide interaction.

Authors:  D G Waller; D Waller
Journal:  Br J Rheumatol       Date:  1984-02

6.  Sulfonamide-sulfonylurea interaction.

Authors:  H S Tucker; J I Hirsch
Journal:  N Engl J Med       Date:  1972-01-13       Impact factor: 91.245

7.  Glucose intolerance with atypical antipsychotics.

Authors:  Karin Hedenmalm; Staffan Hägg; Malin Ståhl; Orjan Mortimer; Olav Spigset
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

8.  Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.

Authors:  Yan-Ling He; Monica Ligueros-Saylan; Gangadhar Sunkara; Ron Sabo; Charlie Zhao; Yibin Wang; Joelle Campestrini; Francoise Pommier; Kiran Dole; Alan Marion; William P Dole; Dan Howard
Journal:  J Clin Pharmacol       Date:  2007-11-06       Impact factor: 3.126

9.  Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Authors:  Yan-Ling He; Ron Sabo; Gilles-Jacques Riviere; Gangadhar Sunkara; Selene Leon; Monica Ligueros-Saylan; Mitchell Rosenberg; William P Dole; Dan Howard
Journal:  Curr Med Res Opin       Date:  2007-05       Impact factor: 2.580

10.  Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

Authors:  Michael Bodmer; Christian Meier; Stephan Krähenbühl; Susan S Jick; Christoph R Meier
Journal:  Diabetes Care       Date:  2008-09-09       Impact factor: 17.152

View more
  13 in total

Review 1.  Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions.

Authors:  S Hennessy; C E Leonard; J J Gagne; J H Flory; X Han; C M Brensinger; W B Bilker
Journal:  Clin Pharmacol Ther       Date:  2015-11-23       Impact factor: 6.875

2.  Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics.

Authors:  Charles E Leonard; Colleen M Brensinger; Warren B Bilker; Stephen E Kimmel; Xu Han; Young Hee Nam; Joshua J Gagne; Margaret J Mangaali; Sean Hennessy
Journal:  Int J Cardiol       Date:  2016-11-12       Impact factor: 4.164

3.  The influence of fibrate initiation on INR and warfarin dose in patients receiving chronic warfarin therapy.

Authors:  John F Polnak; Thomas Delate; Nathan P Clark
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

Review 4.  Clinically and pharmacologically relevant interactions of antidiabetic drugs.

Authors:  Marcus May; Christoph Schindler
Journal:  Ther Adv Endocrinol Metab       Date:  2016-03-31       Impact factor: 3.565

5.  Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics.

Authors:  C E Leonard; W B Bilker; C M Brensinger; X Han; J H Flory; D A Flockhart; J J Gagne; S Cardillo; S Hennessy
Journal:  Clin Pharmacol Ther       Date:  2016-01-17       Impact factor: 6.875

6.  DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case-Control Study.

Authors:  Niranjan Kathe; Anuj Shah; Qayyim Said; Jacob T Painter
Journal:  Diabetes Ther       Date:  2017-12-13       Impact factor: 2.945

Review 7.  Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review.

Authors:  Matthew G Cehic; Nishant Nundall; Jerry R Greenfield; Peter S Macdonald
Journal:  J Transplant       Date:  2018-01-29

8.  Osteogenesis of adipose-derived stem cells from patients with glucose metabolism disorders.

Authors:  Aleksandra Skubis-Sikora; Bartosz Sikora; Agnieszka Witkowska; Urszula Mazurek; Joanna Gola
Journal:  Mol Med       Date:  2020-07-02       Impact factor: 6.354

9.  Potential Drug-Drug Interactions in Patients With Urinary Tract Infections: A Contributing Factor in Patient and Medication Safety.

Authors:  Sidra Noor; Mohammad Ismail; Fahadullah Khan
Journal:  Front Pharmacol       Date:  2019-09-17       Impact factor: 5.810

Review 10.  Practical combination therapy based on pathophysiology of type 2 diabetes.

Authors:  Philip A Levin
Journal:  Diabetes Metab Syndr Obes       Date:  2016-10-31       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.